Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.

Front Immunol · 2022 · PMC8922415 · PMID 35300339

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

In addition, although the percentage of CD3 + T cells and NK cells showed an increasing trend, the level of CD4 + T cells and CD4 + /CD8 + ratio showed a decreasing trend, and the differences were not statistically significant ( Figure 2 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.